The present disclosure relates to a system and method for alerting users to physiological conditions, more particularly, to a medical device configured to inform a user of the presence of patterns that may indicate the presence of sleep apnea.
This section is intended to introduce the reader to various aspects of art that may be related to various aspects of the present disclosure, which are described and/or claimed below. This discussion is believed to be helpful in providing the reader with background information to facilitate a better understanding of the various aspects of the present disclosure. Accordingly, it should be understood that these statements are to be read in this light, and not as admissions of prior art.
Obstructive sleep apnea is a condition in which a patient's breathing is temporarily interrupted when sleeping. The condition is believed to be associated with increased fat deposits in the neck, which commonly occur as a patient ages. These increased fat deposits may lead to a narrowing of the airway. When muscle tone diminishes during sleep, the narrowed airway can collapse during inhalation, effectively blocking air movement. The patient attempts to inhale more deeply, further collapsing the airway. With no air movement, the oxygen level in the patient's bloodstream falls, finally reaching a point where the patient is aroused out of sleep. Upon arousal, the muscle tone increases, the airway opens, and air flow to the lungs is precipitously restored. The patient hyperventilates, which quickly restores the blood oxygen levels to normal levels. The period of arousal may be brief, so the patient is often unaware that the event took place. The patient returns to sleeping, and the cycle often repeats.
Over the years, this repeating cycle of low oxygen levels in the bloodstream can damage the heart and lead to other medical complications. Obstructive sleep apnea is believed to be one of the most common disorders in the United States. However, unlike other common medical disorders, such as diabetes, no simple diagnostic test has been developed to determine if a patient has sleep apnea. Tests do exist that can be used to diagnose sleep apnea, but the tests typically involve an overnight sleep study, which can be costly and inconvenient. The need for a simple, low-cost diagnostic test has led medical personnel to try less expensive techniques, such as pulse oximetry, to diagnose the presence of obstructive sleep apnea.
Advantages of the disclosure may become apparent upon reading the following detailed description and upon reference to the drawings in which:
One or more specific embodiments of the present disclosure will be described below. In an effort to provide a concise description of these embodiments, not all features of an actual implementation are described in the specification. It should be appreciated that in the development of any such actual implementation, as in any engineering or design project, numerous implementation-specific decisions must be made to achieve the developers' specific goals, such as compliance with system-related and business-related constraints, which may vary from one implementation to another. Moreover, it should be appreciated that such a development effort might be complex and time consuming, but would nevertheless be a routine undertaking of design, fabrication, and manufacture for those of ordinary skill having the benefit of this disclosure.
Medical devices may be used to obtain or calculate signals representing physiological parameters from patients, such as SpO2 signals related to a patient's level of blood oxygenation. However, these signals, which are sequences of numerical values of a physiological parameter over time, may have too much information or noise to be effectively used in the diagnosis or treatment of certain medical conditions. Accordingly, the signals may be processed to generate alerts, which may provide a more useful representation of the status of the medical condition. Embodiments of the present techniques provide methods that may be useful for generating indicators of a physiological status, based on a signal representing the blood oxygen saturation (SpO2) level in a patient and, thus, alerting a practitioner to physiologically important conditions.
The indicators may be directly related to the presence of obstructive sleep apnea and may assist practitioners in the diagnosis and treatment of this condition. In embodiments, SpO2 data collected on a pulse oximeter may be used to calculate or determine the alerts. The relative simplicity of this device could enhance the diagnosis of obstructive sleep apnea by allowing patients to take diagnostic equipment home for use overnight and return the equipment to a practitioner for analysis and diagnosis.
Previous studies have examined the possibility of generating a single index reflective of sleep apnea from pulse oximetry data, such as an airway instability index, but many have used schemes that may either be challenging for a practitioner to implement in a treatment setting or overly sensitive to changes. As embodiments may be implemented using current medical devices, their implementation may be easier to explain and use than a more complex calculation for an airway instability index.
The microprocessor 16 may also be coupled to a network interface 26 for the transfer of data from the microprocessor 16 to devices coupled to a local area network 28. The transferred data may, for example, include signal data, indices including an airway instability index, alert signals, alarm signals, or any combination thereof. The transferred data may also consist of control signals from the devices on the local area network 28, for example, to instruct the medical device 10 to send signal data, or other information, to a device on the local area network 28.
In an embodiment, the medical device 10 may be used to alert a practitioner to a physiological condition using data collected from the sensor 12. The alert may be output to the display unit 24 or sent to a network device on the local area network 28. The processing may take place in real time, or may be run after the data collection may be completed for later identification of the physiological condition.
In another embodiment, a network device located on the local area network 28 may be configured to alert a practitioner to the presence of a physiological condition using the data collected from the sensor 12. In this embodiment, the network device may request that the signal be sent from the medical device 10 through the network interface 26. As for the embodiment discussed above, the network device may be used to either determine the alert signal in real time or to process a previously collected signal for later identification of the physiological condition.
In either of the embodiments above, the alert signals may appear on devices on the local area network 28, for example, a patient monitoring screen in an ICU. Alternatively, the alert signals may appear on the display unit 24 of the medical device 10. In embodiments, an alert signal may be activated in both locations using the results from either a local calculation on the medical device 10 or from a remote calculation on a network device coupled to the local area network 28.
The microprocessor 16 may also be coupled to a treatment device 30. For example, the treatment device 30 may be a positive pressure mask used to supply air at an increased pressure to maintain an open airway. In an embodiment, the treatment device 30 may be controlled by the microprocessor 16, for example, activating the treatment device 30 to open an airway based on the alert signals. This control may be useful in helping to confirm a diagnosis of obstructive sleep apnea, as restoration of the airway may restore blood oxygen levels to more normal levels.
A diagnosis of sleep apnea may also be aided by the sound the patient may be making during the sleep apnea events. For example, cessation of breathing following by a sudden gasping intake of breath may provide or confirm the diagnosis. However, such events may be irregularly spaced or may be separated by large time intervals, making any continuous audio recording of the patient tedious and/or expensive to analyze. An audio recording device 32 may be coupled to the microprocessor 16 for recording sounds made by the patient. In an embodiment, the microprocessor 16 may activate the audio recording device 32 based on the alert signals and record patient sounds when a sleep apnea event may be likely to be occurring. When combined with the alert signals, the sound recordings are likely to provide a positive diagnosis of obstructive sleep apnea.
Exemplary embodiments activate alert signals on the value of two general conditions. The first condition may be the presence or absence of clusters in the SpO2 signal, as discussed below. The second condition may be the value of an integral calculated from the absolute level of the SpO2 signal in comparison to previous set limits. The determination of these conditions is discussed in detail with respect to
The determination of the presence of one or more desaturation patterns 38 may be performed by any number of different techniques. For example, in an embodiment, a single one of the desaturation patterns 38 may be identified by a combination of events, such as when a continuously calculated slope 44 of the SpO2 signal 34 drops to a previously selected value, e.g. −1.5 and the SpO2 signal crosses a predetermined SpO2 level, e.g., 85%. In another embodiment, desaturation patterns 38 may be identified using the methods discussed in U.S. Pat. No. 6,760,608 (hereinafter the '608 patent), incorporated by reference for all purposes as if fully set forth herein. Any number of different numerical values may be used in the determination of the presence of desaturation patterns 38, for example, in embodiments, the value of the slope 44, selected to indicate the start of one of the desaturation patterns 38, may be −0.5, −1.0, −1.5, −2, or any value in between. Further, in embodiments, the predetermined SpO2 level used to indicate the start of one of the desaturation patterns 38 may be 95%, 90%, 85%, 80%, 75%, or any appropriate value in between.
Recurring sleep apnea events may often occur in groups of at least two successive desaturation patterns 38, called a cluster 46. The severity of the apnea may be determined from, for example, the number of desaturation patterns 38 in each cluster 46, the time between each one of the desaturation patterns 38, the slope of the drop 40 in the blood oxygen level during each one of the desaturation patterns 38 or the slope of the recovery 42 of the blood oxygen level as each one of the desaturation patterns 38 ends, among others.
In an embodiment, a medical monitor or electronic device may include a module or a set of programming instructions for detecting desaturation patterns or clusters and for detecting desturation below certain limits.
It should be noted that, in order to detect certain data patterns, embodiments of the present disclosure may utilize systems and methods such as those disclosed in U.S. Pat. Nos. 6,760,608, 6,223,064, 5,398,682, 5,605,151, 6,748,252, U.S. application Ser. No. 11/455,408 filed Jun. 19, 2006, U.S. application Ser. No. 11/369,379 filed Mar. 7, 2006, and U.S. application Ser. No. 11/351,787 filed Feb. 10, 2006. Accordingly, U.S. Pat. Nos. 6,760,608, 6,223,064, 5,398,682, 5,605,151, 6,748,252, U.S. application Ser. No. 11/455,408 filed Jun. 19, 2006, U.S. application Ser. No. 11/369,379 filed Mar. 7, 2006, and U.S. application Ser. No. 11/351,787 filed Feb. 10, 2006 are each incorporated herein by reference in their entirety for all purposes.
The RD feature 102 may be capable of performing an algorithm for detecting reciprocations in a data trend. Specifically, the algorithm of the RD feature 102 may perform a statistical method to find potential reciprocation peaks and nadirs in a trend of SpO2 data. A nadir may be defined as a minimum SpO2 value in a reciprocation. The peaks may include a rise peak (e.g., a maximum SpO2 value in a reciprocation that occurs after the nadir) and/or a fall peak (e.g., a maximum SpO2 value in a reciprocation that occurs before the nadir). Once per second, the RD feature 102 may calculate a 12 second rolling mean and standard deviation of the SpO2 trend. Further, based on these mean and standard deviation values, an upper band and lower band 122 with respect to an SpO2 trend 124, as illustrated by the graph 226 in
Upper Band=mean+standard deviation;
Lower Band=mean−standard deviation.
Once the upper band 120 and lower band 122 have been determined, potential reciprocation peaks and nadirs may be extracted from the SpO2 trend 124 using the upper band 120 and the lower band 124. Indeed, a potential peak may be identified as the highest SpO2 point in a trend segment which is entirely above the upper band 120. Similarly, a potential nadir may be identified as the lowest SpO2 point in a trend segment that is entirely below the lower band 122. In other words, peaks identified by the RD feature 102 may be at least one standard deviation above the rolling mean, and nadirs identified by the RD feature 102 may be at least one standard deviation below the mean. If there is more than one minimum value below the lower band 122, the last (or most recent) trend point may be identified as a nadir. If more than one maximum value is above the upper band 120, the point identified as a peak may depend on where it is in relation to the nadir. For example, regarding potential peaks that occur prior to a nadir (e.g., fall peaks) the most recent maximum trend point may be used. In contrast, for peaks that occur subsequent to a nadir (e.g., rise peaks), the first maximum point may be used. In the example trend data represented in
In one embodiment, a window size for calculating the mean and standard deviation may be set based on historical values (e.g., average duration of a set number of previous reciprocations). For example, in one embodiment, a window size for calculating the mean and standard deviation may be set to the average duration of all qualified reciprocations in the last 6 minutes divided by 2. In another embodiment, an adaptive window method may be utilized wherein the window size may be initially set to 12 seconds and then increased as the length of qualified reciprocations increases. This may be done in anticipation of larger reciprocations because reciprocations that occur next to each other tend to be of similar shape and size. If the window remained at 12 seconds, it could potentially be too short for larger reciprocations and may prematurely detect peaks and nadirs. The following equation or calculation is representative of a window size determination, wherein the output of the filter is inclusively limited to 12-36 seconds, and the equation is executed each time a new reciprocation is qualified:
If no qualified reciprocations in the last 6 minutes:
Window Size=12(initial value)
else:
RecipDur=½*current qualified recip duration+½*previous RecipDur
Window Size=bound(RecipDur,12,36).
With regard to SpO2 signals that are essentially flat, the dynamic window method may fail to find the three points (i.e., a fall peak, a rise peak, and a nadir) utilized to identify a potential reciprocation. Therefore, the RD feature 102 may limit the amount of time that the dynamic window method can search for a potential reciprocation. For example, if no reciprocations are found in 240 seconds plus the current adaptive window size, the algorithm of the RD feature 102 may timeout and begin to look for potential reciprocations at the current SpO2 trend point and later. The net effect of this may be that the RD feature 102 detects potential reciprocations less than 240 seconds long.
Once potential peaks and nadirs are found using the RD feature 102, the RQ feature 104 may pass the potential reciprocations through one or more qualification stages to determine if a related event is caused by ventilatory instability. A first qualification stage may include checking reciprocation metrics against a set of limits (e.g., predetermined hard limits). A second qualification stage may include a linear qualification function. In accordance with present embodiments, a reciprocation may be required to pass through both stages in order to be qualified.
As an example, in a first qualification stage, which may include a limit-based qualification, four metrics may be calculated for each potential reciprocation and compared to a set of limits. Any reciprocation with a metric that falls outside of these limits may be disqualified. The limits may be based on empirical data. For example, in some embodiments, the limits may be selected by calculating the metrics for potential reciprocations from sleep lab data where ventilatory instability is known to be present, and then comparing the results to metrics from motion and breathe-down studies. The limits may then be refined to filter out true positives.
The metrics referred to above may include fall slope, magnitude, slope ratio, and path length ratio. With regard to fall slope, it may be desirable to limit the maximum fall slope to filter out high frequency artifact in the SpO2 trend, and limit the minimum fall slope to ensure that slow SpO2 changes are not qualified as reciprocations. Regarding magnitude, limits may be placed on the minimum magnitude because of difficulties associated with deciphering the difference between ventilatory instability reciprocations and artifact reciprocations as the reciprocation size decreases, and on the maximum magnitude to avoid false positives associated with sever artifact (e.g., brief changes of more than 35% SpO2 that are unrelated to actual ventilatory instability). The slope ratio may be limited to indirectly limit the rise slope for the same reasons as the fall slope is limited and because ventilatory instability patterns essentially always have a desaturation rate that is slower than the resaturation (or recovery) rate. The path length ratio may be defined as Path Length/((Fall Peak−Nadir)+(Rise Peak−Nadir)), where Path Length=Σ|Current SpO2 Value−Previous SpO2 value| for all SpO2 values in a reciprocation, and the maximum path length ratio may be limited to limit the maximum standard deviation of the reciprocation, which limits high frequency artifact. The following table (Table I) lists the above-identified metrics along with their associated equations and the limits used in accordance with one embodiment:
As indicated in Table I above, an oximetry algorithm in accordance with present embodiments may operate in two response modes: Normal Response Mode or Fast Response Mode. The selected setting may change the SpO2 filtering performed by the oximetry algorithm, which in turn can cause changes in SpO2 patterns. Therefore a saturation pattern detection feature may also accept a response mode so that it can account for the different SpO2 filtering. Table I indicates values associated with both types of response mode with regard to the Fall Slope values.
A second qualification stage of the RQ feature 204 may utilize a object reciprocation qualification feature. Specifically, the second qualification stage may utilize a linear qualification function based on ease of implementation, efficiency, and ease of optimization. The equation may be determined by performing a least squares analysis. For example, such an analysis may be performed with MATLAB®. The inputs to the equation may include the set of metrics described below. The output may be optimized to a maximum value for patterns where ventilatory instability is known to be present. The equation may be optimized to output smaller values (e.g., 0) for other data sets where potential false positive reciprocations are abundant.
To simplify optimization, the equation may be factored into manageable sub-equations. For example, the equation may be factored into sub-equation 1, sub-equation D, and sub-equation 2, as will be discussed below. The output of each sub-equation may then be substituted into the qualification function to generate an output. The outputs from each of the sub-equations may not be utilized to determine whether a reciprocation is qualified in accordance with present embodiments. Rather, an output from a full qualification function may be utilized to qualify a reciprocation. It should be noted that the equations set forth in the following paragraphs describe one set of constants. However, separate sets of constants may be used based on the selected response mode. For example, a first set of constants may be used for the Normal Response Mode and a second set of constants may be used for the Fast Response Mode.
Preprocessing may be utilized in accordance with present embodiments to prevent overflow for each part of the qualification function. The tables (Tables II-VII) discussed below, which relate to specific components of the qualification function may demonstrate this overflow prevention. Each row in a table contains the maximum value of term which is equal to the maximum value of the input variable multiplied by the constant, wherein the term “maximum” may refer to the largest possible absolute value of a given input. Each row in a table contains the maximum intermediate sum of the current term and all previous terms. For example, a second row may contain the maximum output for the second term calculated, as well as the maximum sum of terms 1 and 2. It should be noted that the order of the row may match the order that the terms are calculated by the RQ feature 204. Further, it should be noted that in the tables for each sub-equation below, equations may be calculated using temporary signed 32-bit integers, and, thus, for each row in a table where the current term or intermediate term sum exceeds 2147483647 or is less than −2147483647 then an overflow/underflow condition may occur.
A first sub-equation, sub-equation 1, may use metrics from a single reciprocation. For example, sub-equation 1 may be represented as follows:
Eq1Score=SlopeRatio*SrCf+PeakDiff*PdCf+FallSlope*FsCf+PathRatio*PrCf+Eq1Offset,
where SrCf, PdCf, FsCf, PrCf, and Eq1Offset may be selected using least squares analysis (e.g., using MATLAB®). PeakDiff may be defined as equal to |Recip Fall Peak−Recip Rise Peak|. It should be noted that PeakDiff is typically not considered in isolation but in combination with other metrics to facilitate separation. For example, a true positive reciprocation which meets other criteria but has a high peak difference could be an incomplete recovery. That is, a patient's SpO2 may drop from a baseline to a certain nadir value, but then fail to subsequently recover to the baseline. However, when used in combination with other metrics in the equation, PeakDiff may facilitate separation of two classifications, as large peak differences are more abundant in false positive data sets.
With regard to sub-equation 1, the tables (Tables II and III) set forth below demonstrate that the inputs may be preprocessed to prevent overflow. Further, the tables set forth below include exemplary limits that may be utilized in sub-equation 1 in accordance with present embodiments. It should be noted that Table II includes Fast Response Mode constants and Table III includes Normal Response Mode constants.
A second sub-equation, sub-equation D, may correspond to a difference between two consecutive reciprocations which have passed the hard limit qualifications checks, wherein consecutive reciprocations include two reciprocations that are separated by less than a defined time span. For example, consecutive reciprocations may be defined as two reciprocations that are less than 120 seconds apart. The concept behind sub-equation D may be that ventilatory instability tends to be a relatively consistent event, with little change from one reciprocation to the next. Artifact generally has a different signature and tends to be more random with greater variation among reciprocations. For example, the following equation may represent sub-equation D:
EqD=SlopeRatioDiff*SrDCf+DurationDiff*DDCf+NadirDiff*NdCf+PathLengthRatioDiff*PrDCf_EqDOffset,
where, SrDCf, DDCf, NdCf, PrDCf, and EqDOffset may be selected using least squares analysis (e.g., using MATLAB®). With regard to other variables in sub-equation D, SlopeRatioDiff may be defined as |Current Recip Slope Ratio−Slope Ratio of last qualified Recip|; DurationDiff may be defined as |Current Recip Duration−Duration of last qualified Recip|; NadirDiff may be defined as |Current Recip Nadir−Nadir value of last qualified Recip|; and PathLengthRatioDiff may be defined as |Current Recip Path Length Ratio−Path Length Ratio of last qualified Recip|.
With regard to sub-equation D, the tables (Tables IV and V) set forth below demonstrate that the inputs may be preprocessed to prevent overflow. Further, the tables set forth below include exemplary limits that may be utilized in sub-equation D in accordance with present embodiments. It should be noted that Table IV includes Fast Response Mode constants and Table V includes Normal Response Mode constants.
A third sub-equation, sub-equation 2, may combine the output of sub-equation D with the output of sub-equation 1 for a reciprocation (e.g., a current reciprocation) and a previous reciprocation. For example, the following equation may represent sub-equation 2:
Eq2Score=EqDScore*DCf+Eq1ScoreCurrent*CurrEq1Cf+Eq1ScorePrev*PrevEq1Cf,
where DCf, N1Cf, PrevEq1Cf, and Eq2Offset may be selected using least squares analysis (e.g., using MATLAB®). With regard to other variables in sub-equation 2, EqDScore may be described as the output of sub-equation D; Eq1ScoreCurrent may be described as the output of sub-equation 1 for a current reciprocation; and Eq1ScorePrev may be described as the output of sub-equation 1 for the reciprocation previous to the current reciprocation.
With regard to sub-equation 2, the tables (Tables VI and VII) set forth below demonstrate that the inputs may be preprocessed to prevent overflow. Further, the tables set forth below include exemplary limits that may be utilized in sub-equation 2 in accordance with present embodiments. It should be noted that Table VI includes Fast Response Mode constants and Table VII includes Normal Response Mode constants.
A qualification function may utilize the output of each of the equations discussed above (i.e., sub-equation 1, sub-equation D, and sub-equation 2) to facilitate qualification and/or rejection of a potential reciprocation. For example, the output of the qualification function may be filtered with an IIR filter, and the filtered output of the qualification function may be used to qualify or reject a reciprocation. An equation for an unfiltered qualification function output in accordance with present embodiments is set forth below:
QFUnfiltered=Eq1Score*SingleRecipWt*Eq2Cf+N2Score*MultipleRecipWt*Eq2Cf+NConsecRecip*ConsecCf+RecipMax*MaxCf+Artifact %*ArtCf+QFOffset,
where Eq2Cf, ConsecCf, MaxCf, ArtCf, and QFOffset may be selected using least squares analysis (e.g., using MATLAB®), and, as indicated above, Eq1Score may be defined as the output of sub-equation 1.
Other metrics in the unfiltered qualification function include SingleRecipWt, MultipleRecipWt, NConsecRecip, RecipMax, and Artifact %. With regard to SingleRecipWt and MultipleRecipWt, when there are two or more consecutive qualified reciprocations (e.g., qualified reciprocations that are less than 120 seconds apart) present, SingleRecipWt may equal 0 and MultipleRecipWt may equal 1. However, when only a single reciprocation is present, SingleRecipWt may equal 1 and MultipleRecipWt may equal 0.
NConseRecip, which may be defined as equal to max(NConsecRecip′,QFConsecMax), may include a count of the number of consecutive reciprocations (e.g., reciprocations that are less than or equal to 120 seconds apart) that have passed the hard limit checks. The value for NConsecRecip may be reset to 0 whenever a gap between any two partially qualified reciprocations exceeds 120 seconds. This may be based on the fact that ventilatory instability is a relatively long lasting event as compared to artifact. Therefore, as more reciprocations pass the hard limit checks, the qualification function may begin qualifying reciprocations that were previously considered marginal. However, to guard against a situation where something is causing a longer term artifact event (e.g., interference from nearby equipment), the value may be clipped to a maximum value to limit the metrics influence on the qualification function output.
RecipMax, which may be defined as equal to max(Fall Peak, Rise Peak), may facilitate making decisions about marginal reciprocations. Indeed, marginal reciprocations with higher maximum SpO2 values may be more likely to get qualified than marginal reciprocations with lower SpO2 values. It should be noted that this metric works in tandem with the NConsecRecip metric, and multiple marginal reciprocations with lower maximum SpO2 values may eventually, over a long period of time, get qualified due to the NConsecRecip metric.
The metric Artifact % may be defined as an artifact percentage that is equal to 100*Total Artifact Count/Recip Duration, where Total Artifact Count is the number of times and artifact flag was set during the reciprocation. Present embodiments may include many metrics and equations that are used to set the artifact flag. Because of this it is a generally reliable indication of the amount of artifact present in the oximetry system as a whole. Marginal reciprocations with a high Artifact % are less likely to be qualified than marginal reciprocations with a low (or 0) artifact percentage.
A last component of the qualification function may include an infinite impulse response (IIR) filter that includes coefficients that may be tuned manually using a tool (e.g., a spreadsheet) that models algorithm performance. The filtered qualification function may be represented by the following equation, which includes different constants for different modes (e.g., Fast Response Mode and Normal Response Mode):
QFFiltered=SingleRecipWt*QFUnfiltered+((1−a)*QFUnfiltered+a*PrevQFFiltered)*MultipleRecipWt,
where QFUnfiltered may be defined as the current unfiltered qualification function output; PrevQFFiltered may be defined as the previous filtered qualification function output; and where the constat “a” may be set to 0.34 for Fast Response Mode and 0.5 for Normal Response Mode.
The filtered output of the qualification function may be compared to a threshold to determine if the current reciprocation is the result of RAF or artifact. The optimum threshold may theoretically be 0.5. However, an implemented threshold may be set slightly lower to bias the output of the qualification function towards qualifying more reciprocations, which may result in additional qualification of false positives. The threshold may be lowered because, in accordance with present embodiments, a cluster determination portion of the algorithm, such as may be performed by the CD feature 106, may require a certain number (e.g., 5) of fully qualified reciprocations before an index may be calculated, and a certain number (e.g., at least 2) of consecutive qualified reciprocations (with no intervening disqualified reciprocations) within the set of fully qualified reciprocations. Since multiple reciprocations may be required, the clustering detection method may be biased toward filtering out false positives. Accordingly, the reciprocation qualification function threshold may be lowered to balance the two processes.
The CD feature 106 may be capable of performing an algorithm that maintains an internal reciprocation counter that keeps track of a number of qualified reciprocations that are currently present. When the reciprocation counter is greater than or equal to a certain value, such as 5, the clustering state may be set to “active” and the algorithm may begin calculating and reporting the detection of clusters. When clustering is not active (e.g., reciprocation count <5) the algorithm may not report the clusters.
The CD feature 106 may utilize various rules to determine the reciprocation count. For example, when the clustering state is inactive, the following rules may be observed:
In addition to cluster detection, embodiments may also include an integral alarm limit detection feature 109 that is configured to detect if the SpO2 signal 34 drops below a lower limit 48. In the embodiment shown in
The use of an absolute limit, however, may result in numerous alarms that are not necessarily informative. Accordingly, methods may be used to determine the severity of the condition and only alert the practitioner if the condition persists. For example, in an embodiment, the integral alarm limit detection feature 109 may calculate an integral 50 from the SpO2 signal 34 by using a summation of the time the signal 34 may be below the lower limit 48 multiplied by the amount the signal 34 may be below the lower limit 48. Similarly, an upper limit (not shown) may also be used for calculating the integral 50. An integral alarm limit 52 may be selected for alerting a practitioner based on the value of the integral 50. In embodiments, calculation of the integral 50 may be performed by the methods detailed in U.S. Pat. No. 5,865,736 (hereinafter the '736 patent), which is hereby incorporated by reference as if fully set forth herein.
The integral alarm limit detection feature 109 and the CD feature 106 may provide reports or other indications to a user notification feature 108 that may be configured to alert a user if there is one or more of a cluster detection or integral alarm limit violation. Referring back to
CAL=CAS*IAL/100 equation 1.
In this equation, CAL may be the combined alarm limit 54, CAS may be a combined alarm sensitivity set by the user, and IAL may be the integral alarm limit 52 discussed above.
If no integral alarm condition has been detected in block 62, the method may determine if the combined alarm limit 54 has been reached by the integral 50, as shown in block 66. The combined alarm limit 54 may be calculated using the method discussed with respect to equation 1. Further, the combined alarm limit 54 may be set to zero, which would inform the user of the presence of clusters 46, even if the value for the integral 50 was zero. If the combined alarm limit 54 has been reached, the method 56 may inform a practitioner that clusters 46 are present, as shown in block 68. If the combined alarm limit 54 has not been reached, the method 56 may activate no alerts, as shown in block 70. After either blocks 68 or 70, the method 56 may return to block 58 to collect the next SpO2 sample in the SpO2 signal 34.
If a cluster 46 may be not detected in block 60, the method 56 may still determine if the integral 50 has reached the integral alarm limit 52, as shown in block 72. If the integral 50 has not reached the integral alarm limit 52, no alarm may be activated, as shown in block 70. However, if the integral 50 has reached the integral alarm limit 52, the method 56 may inform a practitioner that the integral alarm limit 52 has been reached, as shown in block 74. After activating the alert, the method 56 may return to block 58 to collect the next SpO2 sample in the SpO2 signal 34.
The operation of an embodiment of the method 56 discussed with respect to
While the disclosure is suitable to various modifications and alternative forms, embodiments have been shown by way of example in the drawings and have been described in detail herein. However, it should be understood that the disclosure is not intended to be limited to the particular forms disclosed. Rather, the disclosure is intended to encompass all modifications, equivalents, and alternatives falling within the spirit and scope of this disclosure as defined by the following appended claims.
This application is a continuation of U.S. application Ser. No. 14/286,269, filed May 23, 2014, which is a divisional of U.S. application Ser. No. 12/388,123, filed Feb. 18, 2009, which claims priority to U.S. Provisional Application No. 61/066,182, filed Feb. 19, 2008, the disclosures of which are hereby incorporated in their entirety for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
3638640 | Shaw | Feb 1972 | A |
3926177 | Hardway, Jr. et al. | Dec 1975 | A |
4696307 | Montgieux | Sep 1987 | A |
4714341 | Hamaguri et al. | Dec 1987 | A |
4805623 | Jöbsis | Feb 1989 | A |
4807631 | Hersh et al. | Feb 1989 | A |
4911167 | Corenman et al. | Mar 1990 | A |
4913150 | Cheung et al. | Apr 1990 | A |
4936679 | Mersch | Jun 1990 | A |
4938218 | Goodman et al. | Jul 1990 | A |
4971062 | Hasebe et al. | Nov 1990 | A |
4972331 | Chance | Nov 1990 | A |
4974591 | Awazu et al. | Dec 1990 | A |
5028787 | Rosenthal et al. | Jul 1991 | A |
5065749 | Hasebe et al. | Nov 1991 | A |
5084327 | Stengel | Jan 1992 | A |
5119815 | Chance | Jun 1992 | A |
5122974 | Chance | Jun 1992 | A |
5143078 | Mather et al. | Sep 1992 | A |
5167230 | Chance | Dec 1992 | A |
5190038 | Polson et al. | Mar 1993 | A |
5246003 | DeLonzor | Sep 1993 | A |
5247931 | Norwood | Sep 1993 | A |
5263244 | Centa et al. | Nov 1993 | A |
5275159 | Griebel | Jan 1994 | A |
5279295 | Martens et al. | Jan 1994 | A |
5297548 | Pologe | Mar 1994 | A |
5355880 | Thomas et al. | Oct 1994 | A |
5372136 | Steuer et al. | Dec 1994 | A |
5385143 | Aoyagi | Jan 1995 | A |
5390670 | Centa et al. | Feb 1995 | A |
5413099 | Schmidt et al. | May 1995 | A |
5469845 | DeLonzor et al. | Nov 1995 | A |
5482036 | Diab et al. | Jan 1996 | A |
5483646 | Uchikoga | Jan 1996 | A |
5553614 | Chance | Sep 1996 | A |
5564417 | Chance | Oct 1996 | A |
5575285 | Takanashi et al. | Nov 1996 | A |
5611337 | Bukta | Mar 1997 | A |
5630413 | Thomas et al. | May 1997 | A |
5632272 | Diab et al. | May 1997 | A |
5645059 | Fein et al. | Jul 1997 | A |
5645060 | Yorkey | Jul 1997 | A |
5680857 | Pelikan et al. | Oct 1997 | A |
5692503 | Keunstner | Dec 1997 | A |
5730124 | Yamauchi | Mar 1998 | A |
5758644 | Diab et al. | Jun 1998 | A |
5779631 | Chance | Jul 1998 | A |
5782757 | Diab et al. | Jul 1998 | A |
5786592 | Hök | Jul 1998 | A |
5830136 | DeLonzor et al. | Nov 1998 | A |
5830139 | Abreu | Nov 1998 | A |
5831598 | Kauffert et al. | Nov 1998 | A |
5842981 | Larsen et al. | Dec 1998 | A |
5865736 | Baker et al. | Feb 1999 | A |
5871442 | Madarasz et al. | Feb 1999 | A |
5873821 | Chance et al. | Feb 1999 | A |
5920263 | Huttenhoff et al. | Jul 1999 | A |
5995855 | Kiani et al. | Nov 1999 | A |
5995856 | Mannheimer et al. | Nov 1999 | A |
5995859 | Takahashi | Nov 1999 | A |
6011986 | Diab et al. | Jan 2000 | A |
6064898 | Aldrich | May 2000 | A |
6070098 | Moore-Ede et al. | May 2000 | A |
6081742 | Amano et al. | Jun 2000 | A |
6088607 | Diab et al. | Jul 2000 | A |
6120460 | Abreu | Sep 2000 | A |
6134460 | Chance | Oct 2000 | A |
6150951 | Olejniczak | Nov 2000 | A |
6154667 | Miura et al. | Nov 2000 | A |
6163715 | Larsen et al. | Dec 2000 | A |
6181958 | Steuer et al. | Jan 2001 | B1 |
6181959 | Schöllermann et al. | Jan 2001 | B1 |
6223064 | Lynn | Apr 2001 | B1 |
6230035 | Aoyagi et al. | May 2001 | B1 |
6266546 | Steuer et al. | Jul 2001 | B1 |
6285895 | Ristolainen et al. | Sep 2001 | B1 |
6312393 | Abreu | Nov 2001 | B1 |
6353750 | Kimura et al. | Mar 2002 | B1 |
6397091 | Diab et al. | May 2002 | B2 |
6415236 | Kobayashi et al. | Jul 2002 | B2 |
6419671 | Lemberg | Jul 2002 | B1 |
6438399 | Kurth | Aug 2002 | B1 |
6461305 | Schnall | Oct 2002 | B1 |
6466809 | Riley | Oct 2002 | B1 |
6487439 | Skladnev et al. | Nov 2002 | B1 |
6501974 | Huiku | Dec 2002 | B2 |
6501975 | Diab et al. | Dec 2002 | B2 |
6526301 | Larsen et al. | Feb 2003 | B2 |
6544193 | Abreu | Apr 2003 | B2 |
6546267 | Sugiura et al. | Apr 2003 | B1 |
6549795 | Chance | Apr 2003 | B1 |
6580086 | Schulz et al. | Jun 2003 | B1 |
6584336 | Ali et al. | Jun 2003 | B1 |
6591122 | Schmitt | Jul 2003 | B2 |
6594513 | Jobsis et al. | Jul 2003 | B1 |
6606509 | Schmitt | Aug 2003 | B2 |
6606511 | Ali et al. | Aug 2003 | B1 |
6615064 | Aldrich | Sep 2003 | B1 |
6618042 | Powell | Sep 2003 | B1 |
6622095 | Kobayashi et al. | Sep 2003 | B2 |
6654621 | Palatnik et al. | Nov 2003 | B2 |
6654624 | Diab et al. | Nov 2003 | B2 |
6658276 | Kianl et al. | Dec 2003 | B2 |
6658277 | Wasserman | Dec 2003 | B2 |
6662030 | Khalil et al. | Dec 2003 | B2 |
6668183 | Hicks et al. | Dec 2003 | B2 |
6671526 | Aoyagi et al. | Dec 2003 | B1 |
6671528 | Steuer et al. | Dec 2003 | B2 |
6678543 | Diab et al. | Jan 2004 | B2 |
6684090 | Ali et al. | Jan 2004 | B2 |
6690958 | Walker et al. | Feb 2004 | B1 |
6697658 | Al-Ali | Feb 2004 | B2 |
6708048 | Chance | Mar 2004 | B1 |
6711424 | Fine et al. | Mar 2004 | B1 |
6711425 | Reuss | Mar 2004 | B1 |
6714245 | Ono | Mar 2004 | B1 |
6731274 | Powell | May 2004 | B2 |
6754516 | Mannheimer | Jun 2004 | B2 |
6760608 | Lynn | Jul 2004 | B2 |
6785568 | Chance | Aug 2004 | B2 |
6793654 | Lemberg | Sep 2004 | B2 |
6801797 | Mannheimer et al. | Oct 2004 | B2 |
6801798 | Geddes et al. | Oct 2004 | B2 |
6801799 | Mendelson | Oct 2004 | B2 |
6829496 | Nagai et al. | Dec 2004 | B2 |
6850053 | Daalmans et al. | Feb 2005 | B2 |
6863652 | Huang et al. | Mar 2005 | B2 |
6873865 | Steuer et al. | Mar 2005 | B2 |
6889153 | Dietiker | May 2005 | B2 |
6898451 | Wuori | May 2005 | B2 |
6918878 | Brodnick | Jul 2005 | B2 |
6939307 | Dunlop | Sep 2005 | B1 |
6947780 | Scharf | Sep 2005 | B2 |
6949081 | Chance | Sep 2005 | B1 |
6961598 | Diab | Nov 2005 | B2 |
6983178 | Fine et al. | Jan 2006 | B2 |
6993371 | Kiani et al. | Jan 2006 | B2 |
6996427 | Ali et al. | Feb 2006 | B2 |
7024235 | Melker et al. | Apr 2006 | B2 |
7027849 | Al-Ali | Apr 2006 | B2 |
7030749 | Al-Ali | Apr 2006 | B2 |
7035697 | Brown | Apr 2006 | B1 |
7047056 | Hannula et al. | May 2006 | B2 |
7127278 | Melker et al. | Oct 2006 | B2 |
7162306 | Caby et al. | Jan 2007 | B2 |
7190261 | Al-Ali | Mar 2007 | B2 |
7190995 | Chervin et al. | Mar 2007 | B2 |
7209775 | Bae et al. | Apr 2007 | B2 |
7236811 | Schmitt | Jun 2007 | B2 |
7263395 | Chan et al. | Aug 2007 | B2 |
7272426 | Schmid | Sep 2007 | B2 |
7373193 | Al-Ali et al. | May 2008 | B2 |
7507207 | Sakai et al. | Mar 2009 | B2 |
7639145 | Lawson | Dec 2009 | B2 |
8750953 | Ochs et al. | Jun 2014 | B2 |
20010005773 | Larsen et al. | Jun 2001 | A1 |
20010020122 | Steuer et al. | Sep 2001 | A1 |
20010039376 | Steuer et al. | Nov 2001 | A1 |
20010044700 | Kobayashi et al. | Nov 2001 | A1 |
20020026106 | Khalil et al. | Feb 2002 | A1 |
20020035318 | Mannheimer et al. | Mar 2002 | A1 |
20020038079 | Steuer et al. | Mar 2002 | A1 |
20020042558 | Mendelson | Apr 2002 | A1 |
20020049389 | Abreu | Apr 2002 | A1 |
20020062071 | Diab et al. | May 2002 | A1 |
20020111748 | Kobayashi et al. | Aug 2002 | A1 |
20020133068 | Huiku | Sep 2002 | A1 |
20020156354 | Larson | Oct 2002 | A1 |
20020161287 | Schmitt | Oct 2002 | A1 |
20020161290 | Chance | Oct 2002 | A1 |
20020165439 | Schmitt | Nov 2002 | A1 |
20020198443 | Ting | Dec 2002 | A1 |
20030023140 | Chance | Jan 2003 | A1 |
20030055324 | Wasserman | Mar 2003 | A1 |
20030060693 | Monfre et al. | Mar 2003 | A1 |
20030139687 | Abreu | Jul 2003 | A1 |
20030144584 | Mendelson | Jul 2003 | A1 |
20030220548 | Schmitt | Nov 2003 | A1 |
20030220576 | Diab | Nov 2003 | A1 |
20040010188 | Wasserman | Jan 2004 | A1 |
20040054270 | Pewzner et al. | Mar 2004 | A1 |
20040087846 | Wasserman | May 2004 | A1 |
20040107065 | Al-Ali | Jun 2004 | A1 |
20040127779 | Steuer et al. | Jul 2004 | A1 |
20040171920 | Mannheimer et al. | Sep 2004 | A1 |
20040176670 | Takamura et al. | Sep 2004 | A1 |
20040176671 | Fine et al. | Sep 2004 | A1 |
20040230106 | Schmitt et al. | Nov 2004 | A1 |
20040254481 | Brodnick | Dec 2004 | A1 |
20050080323 | Kato | Apr 2005 | A1 |
20050101850 | Parker | May 2005 | A1 |
20050113651 | Wood et al. | May 2005 | A1 |
20050113656 | Chance | May 2005 | A1 |
20050168722 | Forstner et al. | Aug 2005 | A1 |
20050177034 | Beaumont | Aug 2005 | A1 |
20050192488 | Bryenton et al. | Sep 2005 | A1 |
20050203357 | Debreczeny et al. | Sep 2005 | A1 |
20050228248 | Dietiker | Oct 2005 | A1 |
20050267346 | Faber et al. | Dec 2005 | A1 |
20050283059 | Iyer et al. | Dec 2005 | A1 |
20060009688 | Lamego et al. | Jan 2006 | A1 |
20060015021 | Cheng | Jan 2006 | A1 |
20060020181 | Schmitt | Jan 2006 | A1 |
20060030763 | Mannheimer et al. | Feb 2006 | A1 |
20060052680 | Diab | Mar 2006 | A1 |
20060058683 | Chance | Mar 2006 | A1 |
20060064024 | Schnall | Mar 2006 | A1 |
20060195028 | Hannula et al. | Aug 2006 | A1 |
20060224058 | Mannheimer | Oct 2006 | A1 |
20060247501 | Ali | Nov 2006 | A1 |
20060258921 | Addison et al. | Nov 2006 | A1 |
20070179369 | Baker, Jr. | Aug 2007 | A1 |
20070282212 | Sierra et al. | Dec 2007 | A1 |
20080097175 | Boyce et al. | Apr 2008 | A1 |
Number | Date | Country |
---|---|---|
19640807 | Sep 1997 | DE |
178197 | May 1989 | EP |
0615723 | Sep 1994 | EP |
0630203 | Dec 1994 | EP |
1491135 | Dec 2004 | EP |
1740095 | Jan 2007 | EP |
1821076 | Aug 2007 | EP |
63275325 | Nov 1988 | JP |
3170866 | Jul 1991 | JP |
3238813 | Oct 1991 | JP |
4191642 | Jul 1992 | JP |
4332536 | Nov 1992 | JP |
7124138 | May 1995 | JP |
7136150 | May 1995 | JP |
10216115 | Aug 1998 | JP |
2003194714 | Jul 2003 | JP |
2003210438 | Jul 2003 | JP |
2003275192 | Sep 2003 | JP |
2003339678 | Dec 2003 | JP |
2004008572 | Jan 2004 | JP |
2004113353 | Apr 2004 | JP |
2004135854 | May 2004 | JP |
2004194908 | Jul 2004 | JP |
2004202190 | Jul 2004 | JP |
2004248819 | Sep 2004 | JP |
2004290545 | Oct 2004 | JP |
2005034472 | Feb 2005 | JP |
WO9101678 | Feb 1991 | WO |
WO9221281 | Dec 1992 | WO |
WO9309711 | May 1993 | WO |
WO9403102 | Feb 1994 | WO |
WO9512349 | May 1995 | WO |
WO9639927 | Dec 1996 | WO |
WO9749330 | Dec 1997 | WO |
WO9842249 | Oct 1998 | WO |
WO9842251 | Oct 1998 | WO |
WO9843071 | Oct 1998 | WO |
WO9932030 | Jul 1999 | WO |
WO0021438 | Apr 2000 | WO |
WO0140776 | Jun 2001 | WO |
WO0176461 | Oct 2001 | WO |
WO0176471 | Oct 2001 | WO |
WO03039326 | May 2003 | WO |
WO2005009221 | Feb 2005 | WO |
WO05096931 | Oct 2005 | WO |
WO08122806 | Oct 2008 | WO |
Entry |
---|
Aoyagi, T., et al.; “Analysis of Motion Artifacts in Pulse Oximetry,” Japanese Society ME, vol. 42, p. 20 (1993) (Article in Japanese—contains English summary of article). |
Barreto, A.B., et al.; “Adaptive Cancelation of Motion artifact in Photoplethysmographic Blood Volume Pulse Measurements for Exercise Evaluation,” IEEE-EMBC and CMBEC—Theme 4: Signal Processing, pp. 983-984 (1995). |
Vincente, L.M., et al.; “Adaptive Pre-Processing of Photoplethysmographic Blood Volume Pulse Measurements,” pp. 114-117 (1996). |
Plummer, John L., et al.; “Identification of Movement Artifact by the Nellcor N-200 and N-3000 Pulse Oximeters,” Journal of clinical Monitoring, vol. 13, pp. 109-113 (1997). |
Barnum, P.T., et al.; “Novel Pulse Oximetry Technology Capable of Reliable Bradycardia Monitoring in the Neonate,” Respiratory Care, vol. 42, No. 1, p. 1072 (Nov. 1997). |
Poets, C. F., et al.; “Detection of movement artifact in recorded pulse oximeter saturation,” Eur. J. Pediatr.; vol. 156, pp. 808-811 (1997). |
Masin, Donald I., et al.; “Fetal Transmission Pulse Oximetry,” Proceedings 19th International Conference IEEE-EMBS, Oct. 30-Nov. 2, 1997; pp. 2326-2329. |
Pickett, John, et al.; “Pulse Oximetry and PPG Measurements in Plastic Surgery,” Proceedings—19th International Conference—IEEE-EMBS, Chicago, Illinois, Oct. 30-Nov. 2, 1997, pp. 2330-2332. |
Leahy, Martin J., et al.; “Sensor Validation in Biomedical Applications,” IFAC Modelling and Control in Biomedical Systems, Warwick, UK; pp. 221-226 (1997). |
Barreto, Armando B., et al.; “Adaptive LMS Delay Measurement in dual Blood Volume Pulse Signals for Non-Invasive Monitoring,” IEEE, pp. 117-120 (1997). |
East, Christine E., et al.; “Fetal Oxygen Saturation and Uterine Contractions During Labor,” American Journal of Perinatology, vol. 15, No. 6, pp. 345-349 (Jun. 1998). |
Hayes, Matthew J., et al.; “Quantitative evaluation of photoplethysmographic artifact reduction for pulse oximetry,” SPIE, vol. 3570, pp. 138-147 (Sep. 1998). |
Edrich, Thomas, et al.; “Can the Blood Content of the Tissues be Determined Optically During Pulse Oximetry Without Knowledge of the Oxygen Saturation?—An In-Vitro Investigation,” Proceedings of the 20th Annual International conference of the IEEE Engie in Medicine and Biology Society, vol. 20, No. 6, p. 3072-3075, 1998. |
Hayes, Matthew J., et al.; “Artifact reduction in photoplethysmography,” Applied Optics, vol. 37, No. 31, pp. 7437-7446 (Nov. 1998). |
Such, Hans Olaf; “Optoelectronic Non-invasive Vascular Diagnostics Using multiple Wavelength and Imaging Approach,” Dissertation, (1998). |
Todd, Bryan, et al.; “The Identification of Peaks in Physiological Signals,” Computers and Biomedical Research, vol. 32, pp. 322-335 (1999). |
Rhee, Sokwoo, et al.; “Design of a Artifact-Free Wearable Plethysmographic Sensor,” Proceedings of the First joint BMES-EMBS Conference, Oct. 13-16, 1999, Altanta, Georgia, p. 786. |
Rheineck-Leyssius, Aart t., et al.; “Advanced Pulse Oximeter Signal Processing Technology Compared to Simple Averaging: I. Effect on Frequency of Alarms in the Operating Room,” Journal of clinical Anestesia, vol. 11, pp. 192-195 (1999). |
Kaestle, S.; “An Algorithm for Reliable Processing of Pulse Oximetry Signals Under strong Noise Conditions,” Dissertation Book, Lubeck University, Germany (1999). |
Seelbach-Göbel, Birgit, et al.; “The prediction of fetal acidosis by means of intrapartum fetal pulse oximetry,” Am J. Obstet. Gynecol., vol. 180, No. 1, Part 1, pp. 73-81 (1999). |
Goldman, Julian M.; “Masimo Signal Extraction Pulse Oximetry,” Journal of Clinical Monitoring and Computing, vol. 16, pp. 475-483 (2000). |
Coetzee, Frans M.; “Noise-Resistant Pulse Oximetry Using a Synthetic Reference Signal,” IEEE Transactions on Biomedical Engineering, vol. 47, No. 8, Aug. 2000, pp. 1018-1026. |
Nilsson, Lena, et al.; “Monitoring of Respiratory Rate in Postoperative Care Using a New Photoplethysmographic Technique,” Journal of Clinical Monitoring and Computing, vol. 16, pp. 309-315 (2000). |
Yao, Jianchu, et al.; “Design of a Plug-and-Play Pulse Oximeter,” Proceedings of the Second Joint EMBS-BMES Conference, Houston, Texas, Oct. 23-26, 2002; pp. 1752-1753. |
Kaestle, S.; “Determining Artefact Sensitivity of New Pulse Oximeters in Laboratory Using Signals Obtained from Patient,” Biomedizinische Technik, vol. 45 (2000). |
Cysewska-Sobusaik, Anna; “Metrological Problems With noninvasive Transillumination of Living Tissues,” Proceedings of SPIE, vol. 4515, pp. 15-24 (2001). |
Belal, Suliman Yousef, et al.; “A fuzzy system for detecting distorted plethysmogram pulses in neonates and paediatric patients,” Physiol. Meas., vol. 22, pp. 397-412 (2001). |
Hayes, Matthew J., et al.; “A New Method for Pulse Oximetry Possessing Inherent Insensitivity to Artifact,” IEEE Transactions on Biomedical Engineering, vol. 48, No. 4, pp. 452-461 (Apr. 2001). |
Gehring, Harmut, et al.; “The Effects of Motion Artifact and Low Perfusion on the Performance of a New Generation of Pulse Oximeters in Volunteers Undergoing Hypoxemia,” Respiratory Care, Vo. 47, No. 1, pp. 48-60 (Jan. 2002). |
Jopling, Michae W., et al.; “Issues in the Laboratory Evaluation of Pulse Oximeter Performance,” Anesth Analg, vol. 94, pp. S62-S68 (2002). |
Gostt, R., et al.; “Pulse Oximetry Artifact Recognition Algorithm for Computerized Anaesthetic Records,” Journal of Clinical Monitoring and Computing Abstracts, p. 471 (2002). |
Chan, K.W., et al.; “17.3: Adaptive Reduction of Motion Artifact from Photoplethysmographic Recordings using a Variable Step-Size LMS Filter,” IEEE, pp. 1343-1346 (2002). |
Yamaya, Yoshiki, et al.; “Validity of pulse oximetry during maximal exercise in normoxia, hypoxia, and hyperoxia,” J. Appl. Physiol., vol. 92, pp. 162-168 (2002). |
Yoon, Gilwon, et al.; Multiple diagnosis based on Photo-plethysmography: hematocrit, SpO2, pulse and respiration, Optics in Health Care and Biomedical optics: Diagnostics and Treatment; Proceedings of the SPIE, vol. 4916; pp. 185-188 (2002). |
Tremper, K.K.; “A Second Generation Technique for Evaluating Accuracy and Reliability of Second Generation Pulse Oximeters,” Journal of Clinical Monitoring and Computing, vol. 16, pp. 473-474 (2000). |
Cyrill, D., et al.; “Adaptive Comb Filter for Quasi-Periodic Physiologic Signals,” Proceedings of the 25th Annual International Conference of the IEEE EMBS, Cancun, Mexico, Sep. 17-21, 2003; pp. 2439-2442. |
Stetson, Paul F.; “Determining Heart Rate from Noisey Pulse Oximeter Signals Using Fuzzy Logic,” The IEEE International Conference on Fuzzy Systems, St. Louis, Missouri, May 25-28, 2003; pp. 1053-1058. |
Aoyagi, Takuo; “Pulse oximetry: its invention, theory, and future,” Journal of Anesthesia, vol. 17, pp. 259-266 (2003). |
Lee, C.M., et al.; “Reduction of motion artifacts from photoplethysmographic recordings using wavelet denoising approach,” IEEE EMBS Asian-Pacific Conference on Biomedical Engineering, Oct. 20-22, 2003; pp. 194-195. |
A. Johansson; “Neural network for photoplethysmographic respiratory rate monitoring,” Medical & Biological Engineering & Computing, vol. 41, pp. 242-248 (2003). |
Addison, Paul S., et al.; “A novel time-frequency-based 3D Lissajous figure method and its application to the determination of oxygen saturation from the photoplethysmogram,” Institute of Physic Publishing, Meas. Sci. Technol., vol. 15, pp. L15-L18 (2004). |
Yao, Jianchu, et al.; “A Novel Algorithm to Separate Motion Artifacts from Photoplethysmographic Signals Obtained With a Reflectance Pulse Oximeter,” Proceedings of the 26th Annual International conference of the IEEE EMBS, San Francisco, California, Sep. 2004, pp. 2153-2156. |
Matsuzawa, Y., et al.; “Pulse Oximeter,” Home Care Medicine, pp. 42-45 (Jul. 2004); (Article in Japanese—contains English summary of article). |
Johnston, W.S., et al.; “Extracting Breathing Rate Infromation from a Wearable Reflectance Pulse Oximeter Sensor,” Proceedings of the 26th Annual International conference of the IEEE EMBS, San Francisco, California; Sep. 1-5, 2004; pp. 5388-5391. |
Spigulis, Janis, et al.; “Optical multi-channel sensing of skin blood pulsations,” Optical Sensing, Proceedings of SPIE, vol. 5459, pp. 46-53 (2004). |
Yan, Yong-sheng, et al.; “Reduction of motion artifact in pulse oximetry by smoothed pseudo Wigner-Ville distribution,” Journal of NeuroEngineering and Rehabilitation, vol. 2, No. 3 (9 pages) (Mar. 2005). |
J. Huang, et al.; “Low Power Motion Tolerant Pulse Oximetry,” Abstracts, A7, p. S103. (undated). |
P. Lang, et al.; “Signal Identification and Quality Indicator™ for Motion Resistant Pulse Oximetry,” Abstracts, A10, p. S105. (undated). |
Hamilton, Patrick S., et al.; “Effect of Adaptive Motion-Artifact Reduction on QRS Detection,” Biomedical Instrumentation & Technology, pp. 197-202 (undated). |
Kim, J.M., et al.; “Signal Processing Using Fourier & Wavelet Transform,” pp. II-310-II-311 (undated). |
Odagiri, Y.; “Pulse Wave Measuring Device,” Micromechatronics, vol. 42, No. 3, pp. 6-11 (undated) (Article in Japanese—contains English summary of article). |
Yamazaki, Nakaji, et al.; “Motion Artifact Resistant Pulse Oximeter (Durapulse PA 2100),” Journal of Oral Cavity Medicine, vol. 69, No. 4, pp. 53 (date unknown) (Article in Japanese—contains English summary of article). |
Maletras, Francois-Xavier, et al.; “Construction and calibration of a new design of Fiber Optic Respiratory Plethysmograph (FORP),” Optomechanical Design and Engineering, Proceedings of SPIE, vol. 4444, pp. 285-293 (2001). |
Earthrowl-Gould, T., et al.; “Chest and abdominal surface motion measurement for continuous monitoring of respiratory function,” Proc. Instn Mech Engrs, V215, Part H; pp. 515-520 (2001). |
Relente, A.R., et al.; “Characterization and Adaptive Filtering of Motion Artifacts in Pulse Oximetry using Accelerometers,” Proceedings of the Second joint EMBS-BMES Conference, Houston, Texas, Oct. 23-26, 2002; pp. 1769-1770. |
R. Neumann, et al.; “Fourier Artifact suppression Technology Provides Reliable SpO2,,” Abstracts, A11, p. S105 (undated). |
Number | Date | Country | |
---|---|---|---|
20150342541 A1 | Dec 2015 | US |
Number | Date | Country | |
---|---|---|---|
61066182 | Feb 2008 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12388123 | Feb 2009 | US |
Child | 14286269 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14286269 | May 2014 | US |
Child | 14825982 | US |